PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 9548208-3 1997 AIM: To determine the long-term effects of low-dose captopril or enalapril on insulin sensitivity and lipid parameters in normotensive non-insulin dependent diabetic volunteers. Enalapril 65-74 insulin Homo sapiens 78-85 9476381-8 1997 After six weeks of ACEI administration (enalapril 10 mg) the insulin sensitivity in PTH increased significantly in the majority of investigated parameters (MCRsubmax to 9.7 +/- 3.04 mg/kg.min-1, p < 0.05), in indexes of insulin sensitivity (SI to 54.83 +/- 12.9, p < 0.001 and ISI to 9.34 +/- 4.78 mg/kg/min-1, p < 0.01). Enalapril 40-49 insulin Homo sapiens 61-68 9476381-8 1997 After six weeks of ACEI administration (enalapril 10 mg) the insulin sensitivity in PTH increased significantly in the majority of investigated parameters (MCRsubmax to 9.7 +/- 3.04 mg/kg.min-1, p < 0.05), in indexes of insulin sensitivity (SI to 54.83 +/- 12.9, p < 0.001 and ISI to 9.34 +/- 4.78 mg/kg/min-1, p < 0.01). Enalapril 40-49 insulin Homo sapiens 223-230 11236238-0 2000 [The effect of treatment with enalapril versus losartan on levels of insulin resistance in patients with essential hypertension]. Enalapril 30-39 insulin Homo sapiens 69-76 10192233-0 1999 A double blind comparison of the effects of amlodipine and enalapril on insulin sensitivity in hypertensive patients. Enalapril 59-68 insulin Homo sapiens 72-79 10192233-1 1999 This study compares the effects of a calcium channel blocker (amlodipine) and an angiotensin converting enzyme inhibitor (enalapril) on in vivo insulin sensitivity in patients with essential hypertension. Enalapril 122-131 insulin Homo sapiens 144-151 10192233-12 1999 Amlodipine and enalapril were associated with increments in insulin sensitivity. Enalapril 15-24 insulin Homo sapiens 60-67 9548208-0 1997 A long-term comparison between enalapril and captopril on insulin sensitivity in normotensive non-insulin dependent diabetic volunteers. Enalapril 31-40 insulin Homo sapiens 58-65 8010891-7 1994 During IVGTT, enalapril induced a small decrease in the area under the curve of glucose (placebo 18,966 +/- 732.6 mg/dl.min and enalapril 17,575 +/- 916.1 mg/dl.min) associated with a small increase in the area under the curve of insulin (placebo 3,155 +/- 446.99 mU/ml.min and enalapril 3.577 +/- 393.92 mU/ml.min). Enalapril 14-23 insulin Homo sapiens 230-237 7475056-0 1995 Insulin sensitivity in obese hypertensive dyslipidemic patients treated with enalapril or atenolol. Enalapril 77-86 insulin Homo sapiens 0-7 7475056-1 1995 We evaluated the effects of enalapril [angiotensin converting enzyme (ACE) inhibitor] in comparison with atenolol (beta-blocker) on insulin sensitivity and serum lipoprotein concentration in obese hypertensive dyslipidemic patients. Enalapril 28-37 insulin Homo sapiens 132-139 7475056-6 1995 The sensitivity to insulin improved by 15% (p = 0.03) in the enalapril group and worsened by 17% (p < or = 0.01) in the atenolol group. Enalapril 61-70 insulin Homo sapiens 19-26 7475056-8 1995 The improvement in insulin sensitivity caused by enalapril treatment appears to be an advantage as compared with atenolol treatment in hypertensive obese and dyslipidemic patients, whereas the BP-lowering efficacy of the two drugs is similar. Enalapril 49-58 insulin Homo sapiens 19-26 7555530-11 1995 On multivariate analysis, the baseline renal function, glycemic control, and plasma aldosterone and serum insulin concentrations were all independently related to the changes in blood pressure in the enalapril-treated patients. Enalapril 200-209 insulin Homo sapiens 106-113 7854171-0 1995 Antihypertensive therapy with enalapril improves glucose storage and insulin sensitivity in hypertensive patients with non-insulin-dependent diabetes mellitus. Enalapril 30-39 insulin Homo sapiens 69-76 7854171-4 1995 Peripheral insulin sensitivity, ie, insulin stimulation of glucose utilization, increased approximately 30%, or by 4.3 +/- 1.7 mumol/kg.min (13.1 +/- 2.0 v 17.4 +/- 3.5 mumol/kg.min, P < .05, 0 v 4 weeks) during enalapril treatment, but remained unchanged during placebo treatment (15.4 +/- 2.8 v 15.3 +/- 2.7 mumol/kg.min, respectively). Enalapril 215-224 insulin Homo sapiens 11-18 7854171-7 1995 We conclude that enalapril improves insulin sensitivity by increasing glucose storage in hypertensive patients with NIDDM. Enalapril 17-26 insulin Homo sapiens 36-43 7977316-0 1994 Long-term treatment with either enalapril or nitrendipine stabilizes albuminuria and increases glomerular filtration rate in non-insulin-dependent diabetic patients. Enalapril 32-41 insulin Homo sapiens 129-136 8675251-7 1996 (2) Enalapril significantly improved insulin-resistant lipolysis in the abdominally obese hypertensive subjects. Enalapril 4-13 insulin Homo sapiens 37-44 8770334-0 1995 The effects of increasing doses of enalapril on insulin sensitivity in normotensive non-insulin dependent diabetic subjects. Enalapril 35-44 insulin Homo sapiens 48-55 8770334-3 1995 AIM: To examine the effect of increasing doses of enalapril on insulin sensitivity in normotensive non-insulin dependent diabetic subjects. Enalapril 50-59 insulin Homo sapiens 63-70 8770334-4 1995 METHODS: The effects of increasing doses of enalapril on insulin sensitivity in ten normotensive non-insulin dependent diabetic subjects were measured, using the hyperinsulinaemic isoglycaemic clamp technique. Enalapril 44-53 insulin Homo sapiens 57-64 7794577-0 1995 The effect of enalapril with and without hydrochlorothiazide on insulin sensitivity and other metabolic abnormalities of hypertensive patients with NIDDM. Enalapril 14-23 insulin Homo sapiens 64-71 7794577-7 1995 Plasma triglycerides and fasting plasma insulin decreased significantly after the 16 weeks of enalapril. Enalapril 94-103 insulin Homo sapiens 40-47 7794577-8 1995 Insulin-mediated glucose uptake increased significantly after 8 and 16 weeks of monotherapy with enalapril. Enalapril 97-106 insulin Homo sapiens 0-7 7794577-10 1995 It is concluded that enalapril improves some of the metabolic parameters, including insulin sensitivity, of hypertensive diabetic patients. Enalapril 21-30 insulin Homo sapiens 84-91 8174845-4 1994 In comparison, intravenous administration of an active metabolite of delapril (3.0 mmol.kg-1) and oral administration of either delapril or enalapril (5.0 mmol.kg-1) showed slight, but not significant increases in insulin sensitivity indices and plasma bradykinin concentrations. Enalapril 140-149 insulin Homo sapiens 214-221 8010891-9 1994 The insulin responsiveness to glucose increased significantly from 0.16 +/- 0.020 during placebo to 0.21 +/- 0.023 during enalapril. Enalapril 122-131 insulin Homo sapiens 4-11 8010891-11 1994 CONCLUSION: In hypertensive patients, the treatment with enalapril induced a small increase (not significant) in glucose tolerance caused by a significant rise in insulin responsiveness to glucose since no modification in insulin sensitivity was observed. Enalapril 57-66 insulin Homo sapiens 163-170 8517428-8 1993 With addition of enalapril to the low sodium chloride diet, the insulin area under the curve (14.5 +/- 2.6 mU-min/dl) was not significantly different from that during the high sodium chloride phase. Enalapril 17-26 insulin Homo sapiens 64-71 8141692-0 1993 A comparison between enalapril and captopril on insulin sensitivity in normotensive healthy volunteers. Enalapril 21-30 insulin Homo sapiens 48-55 8141692-2 1993 AIM: To compare the impact of two different ACEIs (captopril and enalapril) on insulin mediated glucose uptake in normotensive, non-obese, insulin sensitive subjects. Enalapril 65-74 insulin Homo sapiens 79-86 8141692-2 1993 AIM: To compare the impact of two different ACEIs (captopril and enalapril) on insulin mediated glucose uptake in normotensive, non-obese, insulin sensitive subjects. Enalapril 65-74 insulin Homo sapiens 139-146 1516522-0 1992 Hypoglycemia induced by enalapril in patient with insulin resistance and NIDDM. Enalapril 24-33 insulin Homo sapiens 50-57 8427295-2 1993 Because blockade of the renin-angiotensin system has been demonstrated to improve insulin sensitivity in hypertensive patients, the authors evaluated the effects of angiotensin-II administration and of angiotensin-converting enzyme inhibition with enalapril on insulin-mediated glucose uptake in normotensive men. Enalapril 248-257 insulin Homo sapiens 261-268 8466592-3 1993 The insulin effect was only partially inhibited by the converting enzyme inhibitors enalapril, quinapril, and quinaprilat, whereas it was markedly or totally blunted by the angiotensin II antagonists DuP753 and PD123177. Enalapril 84-93 insulin Homo sapiens 4-11 8405025-0 1993 Effect of chronic treatment with enalapril on glucose tolerance and serum insulin in non-insulin-resistant Japanese patients with essential hypertension. Enalapril 33-42 insulin Homo sapiens 74-81 8405025-1 1993 The effect of enalapril, an angiotensin converting enzyme inhibitor, on glucose tolerance and serum insulin response to a glucose load has been evaluated in 8 non-obese patients (3 women and 5 men) with untreated essential hypertension (WHO Stage I or II) and without insulin resistance. Enalapril 14-23 insulin Homo sapiens 100-107 24786779-11 2014 The combination treatment lercanidipine + enalapril seems to be more effective than lercanidipine + hydrochlorothiazide in activating insulin signalling in human lympho-monocytes. Enalapril 42-51 insulin Homo sapiens 134-141 1284142-5 1992 A number of studies, both with captopril and with enalapril, have shown small increases in insulin sensitivity, and there is evidence that this is due to enhanced glucose uptake into skeletal muscle. Enalapril 50-59 insulin Homo sapiens 91-98 1752291-7 1991 Insulin sensitivity increased significantly during treatment with enalapril (with enalapril: Ins I: 11.3 +/- 3.0, Ins II: 20.0 +/- 3.4 and Ins III: 20.6 +/- 3.9 mg kg-1 min-1 glucose (mean +/- SD); without enalapril: Ins I: 8.7 +/- 2.3, Ins II: 13.7 +/- 3.0 and Ins III: 15.5 +/- 3.1 mg kg-1 min-1 glucose; P less than 0.05). Enalapril 66-75 insulin Homo sapiens 0-7 1752291-7 1991 Insulin sensitivity increased significantly during treatment with enalapril (with enalapril: Ins I: 11.3 +/- 3.0, Ins II: 20.0 +/- 3.4 and Ins III: 20.6 +/- 3.9 mg kg-1 min-1 glucose (mean +/- SD); without enalapril: Ins I: 8.7 +/- 2.3, Ins II: 13.7 +/- 3.0 and Ins III: 15.5 +/- 3.1 mg kg-1 min-1 glucose; P less than 0.05). Enalapril 82-91 insulin Homo sapiens 0-7 2868454-5 1985 In an open trial in non-insulin-dependent diabetics with arterial hypertension followed-up for 1 year, enalapril administered alone has proved effective and devoid of clinical and biochemical side-effects. Enalapril 103-112 insulin Homo sapiens 24-31 31336455-10 2019 Drugs that had more interaction with insulin were: acetylsalicylic acid (40%), enalapril (18%), losartan (32%) and hydrochlorothiazide (23%). Enalapril 79-88 insulin Homo sapiens 37-44 17227956-6 2007 Vasodilator actions of insulin were significantly improved in MVB from EGCG- or enalapril-treated SHR (when compared with vehicle-treated SHR). Enalapril 80-89 insulin Homo sapiens 23-30 17227956-10 2007 Both enalapril and EGCG treatment of SHR improved insulin sensitivity and raised plasma adiponectin levels. Enalapril 5-14 insulin Homo sapiens 50-57 16685130-0 2006 The use of low-dose insulin in cardiogenic shock due to combined overdose of verapamil, enalapril and metoprolol. Enalapril 88-97 insulin Homo sapiens 20-27 14608527-8 2003 Calculated insulin sensitivity index also improved in the enalapril-treated group (p=0.05) but not in the losartan-treated group, compared with baseline levels. Enalapril 58-67 insulin Homo sapiens 11-18